Obama plans to set up stimulus oversight board

February 2, 2009 23:18


Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analysis from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief


US President Barack Obama said Monday he would set up an independent board to review spending of his economic US$800 billion-plus stimulus plan to pull the nation out of it's deep economic recession. The measure was passed by the House of Representatives last week and is under debate in the Senate, although failing to attract significant Republican support in either legislative chamber as he had hoped. The president also predicted that some of America's troubled banks still could fail, despite a separate $700 billion financial bailout program, half of which has already been spent by the former Bush administration. The president also said that he was taking full responsibility for rescuing the US economy, which is facing its worst downturn in 80 years.

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection